VIDAS vs ELISA in the serodiagnosis of HIV 1 + 2, rubella and toxoplasma.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

VIDAS vs ELISA in the serodiagnosis of HIV 1 + 2, rubella and toxoplasma.

Abstr Gen Meet Am Soc Microbiol. 1994;94:555 (abstract no. C-365). Unique Identifier : AIDSLINE ASM94/94313110
Araj GF; Bizri AR; Fattouh LG; Nassif RE; American Univ. Med. Ctr., Beirut, Lebanon.

Abstract: Rapid, automated and self-contained instruments that minimize exposure to potentially infectious blood samples are attractive addition to the serodiagnostic laboratory. The performance of Vitek Immuno Diagnostic Assay Systems (VIDAS, biomerieux Vitek Inc., Hazelwood, MO) was tried in a developing country for the detection of antibodies to three infectious diseases. Among 87 selected sera which were tested for anti-HIV 1 + 2, 20 and 13 (of the 20) were positive by ELISA (CLONATEC, Paris, France) and VIDAS, respectively. The Western blot (Lia Tek HIV 1 + 2, Organon Teknika, Boxtel, Holland) done on the 20 positive sera confirmed only the 13 which were also positive by VIDAS. Concordant results were obtained for 21 sera (12 positive) tested for anti-rubella IgG by ELISA (Human, Taunusstein, Germany) and VIDAS. Concerning toxoplasma ELISA (Human), IgM and IgG were positive for 5 of 19 and 27 of 27 sera, respectively, while VIDAS was positive for 1 of 19 and 23 of 27 sera, respectively. An arbitrator Toxo ELISA (Organon) for IgG and IgM confirmed the VIDAS results. The sera with discrepant Human Toxo ELISA IgG & IgM had O.D. readings close to the cut-off values. In addition to the above noted characteristics, the VIDAS is a reliable instrument to introduce in the clinical laboratories performing serodiagnosis of infectious diseases.

Keywords: Acquired Immunodeficiency Syndrome/*DIAGNOSIS Antibodies, Protozoan/BLOOD Antibodies, Viral/BLOOD Comparative Study Enzyme-Linked Immunosorbent Assay/*METHODS Human HIV Antibodies/BLOOD HIV-1/*ISOLATION & PURIF HIV-2/*ISOLATION & PURIF IgG/BLOOD IgM/BLOOD Rubella/*DIAGNOSIS Serodiagnosis/*METHODS Toxoplasmosis/*DIAGNOSIS ABSTRACT
941030
M94A0844

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .